Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Diaceutics ( (GB:DXRX) ) has provided an update.
Diaceutics PLC reported a strong performance in the first half of 2025, with a 22% revenue growth on a constant currency basis, reaching £14.6 million. The company has demonstrated significant commercial momentum, with a 16% increase in annual recurring revenue and a strong order book of £29.4 million. Diaceutics continues to expand its customer base, working with 74 therapeutic brands across 43 customers, including 18 of the top 20 global pharma companies. The company remains debt-free with £10.4 million in cash, supporting ongoing investment in product innovation and commercial growth. The outlook for the second half of 2025 is positive, with expectations for continued margin improvement and market expansion beyond precision medicine.
The most recent analyst rating on (GB:DXRX) stock is a Buy with a £185.00 price target. To see the full list of analyst forecasts on Diaceutics stock, see the GB:DXRX Stock Forecast page.
Spark’s Take on GB:DXRX Stock
According to Spark, TipRanks’ AI Analyst, GB:DXRX is a Neutral.
Diaceutics’ strong revenue growth and strategic corporate events contribute positively to the score. However, profitability challenges and a lack of a positive valuation component dampen the overall outlook. Technical indicators are mixed, suggesting cautious investor sentiment.
To see Spark’s full report on GB:DXRX stock, click here.
More about Diaceutics
Diaceutics PLC is a leading technology and solutions provider to the pharmaceutical and biotech industry, focusing on the commercialization of precision medicines. The company offers an end-to-end solution through data analytics, scientific, and advisory services enabled by its DXRX platform, The Diagnostics Network®.
Average Trading Volume: 139,730
Technical Sentiment Signal: Buy
Current Market Cap: £108.6M
See more insights into DXRX stock on TipRanks’ Stock Analysis page.